Patricia Louis is a content editor and social media strategist with a strong background in journalism, public relations and business. As the organic social media editor, she oversees and develops ...

The Food and Drug Administration on April 30 proposed excluding Novo Nordisk and Eli Lilly's weight-loss drugs from a key compounding list, potentially limiting large-scale production by outsourcing ...

FDA proposes excluding blockbuster weight-loss drugs from 503B compounding list Move could limit bulk production by outsourcing facilities Novo and Lilly support FDA stance If finalized, the move ...

Weight-loss company Noom has acquired 503A pharmacy Tailor Made Compounding, which Noom said will allow it to expand its behavior change programs and move beyond weight health. Tailor Made provides ...

Replace the legacy repo-local config and storage assumptions with a two-scope state model: user_state_dir for user-level CE state and per-project durable storage repo_state_dir for repo-local CE ...

Eli Lilly stressed that tirzepatide has never been studied in combination with vitamin B12 and warned that the compounders making these products aren’t required to monitor and report potential ...

New warning letters follow an FDA crackdown on GLP-1 drug compounding that intensified last month with explicit pledges of "swift action." (iStock / Getty Images Plus) The FDA is taking no prisoners ...

As GLP-1s remain popular across the U.S., the Food and Drug Administration says it’s now prepared to rein in a fast-growing corner of the market: compounding pharmacies and telehealth companies that ...

People who order low-cost versions of the wildly popular weight-loss drugs Wegovy and Zepbound from so-called compounding pharmacies might soon see disruptions in their medication. The U.S. Food and ...

The US Food and Drug Administration (FDA) recently issued warning letters to more than 40 compounding pharmacies, demanding that they cease certain advertising practices for a variety of compounded ...

This article reviews the safety, efficacy, and regulatory concerns related to compounded semaglutide, with a focus on how health care providers can offer guidance and education to patients.

A compounding pharmacy in Amherst is in trouble with the law after hiring a third-party company to help get prescriptions approved by insurers, including Medicare, with many of them allegedly being ...